Verastem, Inc.
VS-7375
advanced KRAS G12D solid tumors
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on VS-7375 for advanced KRAS G12D solid tumors is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“Engage with the FDA in 1H 2026 to discuss its development path forward, including potential registration-directed clinical trials in PDAC, NSCLC, and CRC.”